Health
Australia set to host clinical trial of genetically modified Covid nasal spray vaccine – The Guardian
Australian company applies for permission to conduct trial of men and women aged 18 to 55
Vaccines and immunisationAustralian company applies for permission to conduct trial of men and women aged 18 to 55
Australia is set to host the first human clinical trial of a genetically modified adenovirus vaccine for Covid-19 delivered via nasal spray.
Avance Clinical, an Australian contract research organisation, has applied to the office of the gene technology regulator for permission to conduct the phase 1 clinical trial on behalf US company Tetherex Pharmaceuticals Corporation.
The trial…
-
Noosa News23 hours agoThe grey backstreet of Brisbane’s Fortitude Valley where Arnie the missing dog was found dead in his owner Nathan McKeown’s black ute
-
General7 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
Noosa News22 hours agoSeven key takeaways from the Queensland probe’s first week
-
General13 hours agoCritically endangered orchid thrives as NSW Mid North Coast cemetery provides habitat refuge